What question did this study set out to answer?

To review the clinical validity, clinical utility, and ongoing methodological challenges of Ki67 assessment as a proliferation biomarker in early breast cancer.

January 1, 2022SHILAP Revista de lepidopterologíaOpen Access

Clinical validity and clinical utility of Ki67 in early breast cancer

View Full Paper

Ask AI

Bookmark

Authors

HKHans KreipeMedizinische Hochschule Hannover NHNadia HarbeckBreast Center MCMatthias ChristgenMedizinische Hochschule Hannover

Discussion

Member takes

Implication

Evidence review demonstrates the prognostic validity and clinical utility of Ki67 in early breast cancer, highlighting its role in guiding endocrine therapy despite ongoing standardization challenges.

Key Points

To review the clinical validity, clinical utility, and ongoing methodological challenges of Ki67 assessment as a proliferation biomarker in early breast cancer.
Synthesized findings from prospective clinical trials and large observational studies examining Ki67 immunohistochemistry in early breast cancer.
Evaluated methodological variables affecting Ki67 assessment, including antibody clone choice, scoring techniques, inter-laboratory reproducibility, and computer-assisted image analysis.
Ki67 dynamics following short-term preoperative endocrine therapy reliably differentiate endocrine-sensitive from endocrine-resistant early breast cancers.
Standardized central pathology assessment in prospective trials demonstrates clinical validity, while large observational cohorts confirm clinical utility for risk stratification.
Methodological consensus remains unresolved regarding optimal antibody clones, scoring protocols, inter-laboratory reproducibility, and artificial intelligence-assisted imaging.

Cite This Study

Kreipe et al. (2022) studied this question.

synapsesocial.com/papers/69d72916523bf2ea07f5097d https://doi.org/10.1177/17588359221122725

View Full Paper

Ask AI

Bookmark

Clinical validity and clinical utility of Ki67 in early breast cancer

Discussion

Member takes

Implication

Key Points

Cite This Study

Clinical validity and clinical utility of Ki67 in early breast cancer

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider